<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03580837</url>
  </required_header>
  <id_info>
    <org_study_id>6788</org_study_id>
    <nct_id>NCT03580837</nct_id>
  </id_info>
  <brief_title>Breast MRI for Neaodjuvant Chemotherapy Response Prediction and Evaluation in Breast Cancer</brief_title>
  <official_title>Breast MRI for Neaodjuvant Chemotherapy Response Prediction and Evaluation in Breast Cancer, With Focus on Background Parenchymal Enhancement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this retrospective study is to evaluate the value of pre-treatment and
      post-treatment multimodality MRI study, including quantitative evaluation of background
      parenchymal enhancement, for response prediction and evaluation. This study will include 100
      patients treated in a single institution between 2011 and 2016
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Presence or absence of of pathologic enhancement of breast by MRI</measure>
    <time_frame>1 hour after the realization of the MRI</time_frame>
    <description>This work concerns 110 patients treated with neoadjuvant chemotherapy for breast cancer and having received a breast MRI in pre and post-chemiotherapy at the Hautepierre Hospital.</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Breast Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with breast cancer treated with neoadjuvant chemotherapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients

          -  Patients with breast cancer treated with neoadjuvant chemotherapy

          -  Patients with pre- and post-chemotherapy MRI

          -  Patients who have given their agreement to use their data for research purposes.

        Exclusion Criteria:

        - Refusal to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sébastien MOLIERE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Strasbourg, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sébastien MOLIERE, MD</last_name>
    <phone>33 3 88 12 78 65</phone>
    <email>sebastien.moliere@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie-Noëlle ROEDLICH, MD</last_name>
    <phone>33 3 88 12 78 65</phone>
    <email>marie-noelle.roedlich@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service Imagerie 1</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sébastien MOLIERE, MD</last_name>
      <phone>33 3 88 12 78 65</phone>
      <email>sebastien.moliere@chru-strasbourg.fr</email>
    </contact>
    <contact_backup>
      <last_name>Marie-Noëlle ROEDLICH, MD</last_name>
      <phone>33 3 88 12 78 65</phone>
      <email>marie-noelle.roedlich@chru-strasbourg.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Sébastien MOLIERE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Noëlle ROEDLICH, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle ODDOU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carole MATHELIN, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>January 3, 2018</study_first_submitted>
  <study_first_submitted_qc>June 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2018</study_first_posted>
  <last_update_submitted>June 25, 2018</last_update_submitted>
  <last_update_submitted_qc>June 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Neoadjuvant chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

